Phase 2 Trial for an Experimental Epidermolysis Bullosa Treatment Begins Enrollment
chezbeate / Pixabay

Phase 2 Trial for an Experimental Epidermolysis Bullosa Treatment Begins Enrollment

According to a story from epidermolysisbullosanews.com, the biotechnology company TWi Biotechnology, Inc., recently announced that is has begun enrollment for its Phase 2 trial. This trial will test the company's…

Continue Reading Phase 2 Trial for an Experimental Epidermolysis Bullosa Treatment Begins Enrollment
This Drug Could Treat Psoriatic Arthritis and Ankylosing Spondylitis
12019 / Pixabay

This Drug Could Treat Psoriatic Arthritis and Ankylosing Spondylitis

According to a story from globenewswire.com, Galapagos NV and Gilead Sciences, Inc., recently announced that two clinical trials which were recently published in The Lancet demonstrated that the experimental treatment filgotinib could…

Continue Reading This Drug Could Treat Psoriatic Arthritis and Ankylosing Spondylitis
Should Medicine Stop Focusing on Individual Diseases and Start Treating Combinations of Conditions?
rawpixel / Pixabay

Should Medicine Stop Focusing on Individual Diseases and Start Treating Combinations of Conditions?

Multimorbidity, typically defined as having two or more long-term health conditions, has become a topic of increasing focus for healthcare providers. Many elderly people are affected by multimorbidity, with the…

Continue Reading Should Medicine Stop Focusing on Individual Diseases and Start Treating Combinations of Conditions?
Experimental Treatment for ITP Gets Orphan Drug Designation
mohamed_hassan / Pixabay

Experimental Treatment for ITP Gets Orphan Drug Designation

According to a story from financialbuzz.com, the biopharmaceutical company Principia Biopharma recently announced that its experimental medical product PRN1008 has received Orphan Drug designation from the US Food and Drug…

Continue Reading Experimental Treatment for ITP Gets Orphan Drug Designation
FDA Approves Investigational New Drug Application For an Experimental Treatment for Guillain-Barre Syndrome
RobinHiggins / Pixabay

FDA Approves Investigational New Drug Application For an Experimental Treatment for Guillain-Barre Syndrome

According to a story from BioSpace, the biotechnology company Cellenkos, Inc., recently announced that the US Food and Drug Administration (FDA) has given the company the go ahead to begin…

Continue Reading FDA Approves Investigational New Drug Application For an Experimental Treatment for Guillain-Barre Syndrome
Trial Results are Positive for a Potential Treatment for Contrast-Induced Nephropathy
jarmoluk / Pixabay

Trial Results are Positive for a Potential Treatment for Contrast-Induced Nephropathy

According to a story from markets.businessinsider.com, the drug development company Pharming Group N.V. recently announced results from a Phase II trial testing its medication RUCONEST. This drug was tested as…

Continue Reading Trial Results are Positive for a Potential Treatment for Contrast-Induced Nephropathy